Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Non-Current Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non-Current Assets for 16 consecutive years, with $35.2 million as the latest value for Q1 2026.

  • Quarterly Non-Current Assets rose 30.94% to $35.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $35.2 million through Jan 2026, up 30.94% year-over-year, with the annual reading at $32.8 million for FY2025, 246.5% up from the prior year.
  • Non-Current Assets for Q1 2026 was $35.2 million at PharmaCyte Biotech, up from $33.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $37.3 million in Q3 2024, with the low at $5.1 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $16.8 million, with a median of $9.5 million recorded in 2024.
  • The sharpest move saw Non-Current Assets soared 627.57% in 2024, then plummeted 30.32% in 2025.
  • Over 5 years, Non-Current Assets stood at $5.1 million in 2022, then changed by 0.0% to $5.1 million in 2023, then skyrocketed by 558.28% to $33.8 million in 2024, then decreased by 2.4% to $33.0 million in 2025, then increased by 6.75% to $35.2 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $35.2 million, $33.0 million, and $26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.